Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: J Immunol. 2013 Oct 23;191(11):5542–5550. doi: 10.4049/jimmunol.1301810

Figure III. PD-1/B7.H1 interaction necessary for CD4+ T cell exhaustion during symptomatic VL.

Figure III

Adherent PBMC treated with B7.H1 blocking antibody or IL-10 blocking antibody. PBMC stimulated as previous. (A) CD4+ cellular proliferation (top row) and CD4+ T cell IFNγ (bottom row), compared to PD-1 (x-axis) in PBMC from negative control (left), asymptomatic VL (middle), and symptomatic VL (right) dogs, with isotype control (left), anti-IL-10 antibody (center), or anti-B7.H1 antibody treatment (right). (B) CD4+ cellular proliferation, n=15. (C) CD4+ PBMC IFNγ intracellular production, n=21. (D) Production of IL-10 via ELISA, n=11. **p<0.01, via one way ANOVA with Tukey’s post-test.